Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

by · The Cerbat Gem

Valneva SE (NASDAQ:VALN – Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $6.41, but opened at $6.22. Valneva shares last traded at $6.23, with a volume of 2,395 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on VALN. Guggenheim decreased their target price on Valneva from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Valneva in a report on Tuesday, April 15th.

Read Our Latest Report on Valneva

Valneva Stock Performance

The company has a market capitalization of $522.73 million, a P/E ratio of -48.08 and a beta of 1.81. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The business’s fifty day simple moving average is $6.51 and its 200-day simple moving average is $5.85.

Valneva (NASDAQ:VALN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.27. The business had revenue of $51.79 million for the quarter, compared to analysts’ expectations of $41.80 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, equities analysts anticipate that Valneva SE will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of Valneva

Several hedge funds have recently bought and sold shares of VALN. Wells Fargo & Company MN lifted its stake in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares in the last quarter. ABC Arbitrage SA purchased a new stake in Valneva in the 4th quarter worth $84,000. Finally, GAMMA Investing LLC purchased a new stake in Valneva in the 1st quarter worth $94,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

Recommended Stories